Entry |
|
Name |
Mitoxantrone hydrochloride (JAN/USP); Novantron (TN) |
Product |
|
Generic |
|
Formula |
C22H28N4O6. 2HCl
|
Exact mass |
516.1542
|
Mol weight |
517.40
|
Structure |

|
Simcomp |
|
Class |
Antineoplastic
DG01727 Anthraquinone antineoplastic
DG01529 Topoisomerase inhibitor
DG01527 Topoisomerase II inhibitor
Transporter substrate
DG02861 ABCC2 substrate
DG01913 ABCG2 substrate
|
Remark |
Therapeutic category: | 4291 |
Product (DG00701): | D02166<JP/US> |
|
Efficacy |
Antineoplastic, Topoisomerase II inhibitor |
Disease |
|
Target |
|
Metabolism |
Transporter: ABCG2 [HSA: 9429], ABCC2 [HSA: 1244]
|
Interaction |
|
Structure map |
map07042 | Antineoplastics - agents from natural products |
|
Other map |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
L01DB Anthracyclines and related substances
L01DB07 Mitoxantrone
D02166 Mitoxantrone hydrochloride (JAN/USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Antineoplastics, Miscellaneous
Mitoxantrone
D02166 Mitoxantrone hydrochloride (JAN/USP)
Central Nervous System Agents
Multiple Sclerosis Agents
Mitoxantrone
D02166 Mitoxantrone hydrochloride (JAN/USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D02166 Mitoxantrone hydrochloride (JAN/USP)
Drug groups [BR:br08330]
Antineoplastic
DG01727 Anthraquinone antineoplastic
DG00701 Mitoxantrone
D02166 Mitoxantrone hydrochloride
DG01529 Topoisomerase inhibitor
DG01527 Topoisomerase II inhibitor
DG00701 Mitoxantrone
D02166 Mitoxantrone hydrochloride
Transporter substrate
DG02861 ABCC2 substrate
DG00701 Mitoxantrone
D02166 Mitoxantrone hydrochloride
DG01913 ABCG2 substrate
DG00701 Mitoxantrone
D02166 Mitoxantrone hydrochloride
Target-based classification of drugs [BR:br08310]
Enzymes
Isomerases (EC5)
DNA topoisomerase
TOP2
D02166 Mitoxantrone hydrochloride (JAN/USP) <JP/US>
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D02166
Drug groups [BR:br08330]
Antineoplastic
DG01727 Anthraquinone antineoplastic
DG00701 Mitoxantrone
DG01529 Topoisomerase inhibitor
DG01527 Topoisomerase II inhibitor
DG00701 Mitoxantrone
Transporter substrate
DG02861 ABCC2 substrate
DG00701 Mitoxantrone
DG01913 ABCG2 substrate
DG00701 Mitoxantrone
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 34
1 C8x C 14.8029 -16.3363
2 C8x C 14.8029 -17.7373
3 C8y C 16.0202 -18.4414
4 C8y C 16.0202 -15.6392
5 C8y C 17.2304 -16.3363
6 C8y C 17.2245 -17.7373
7 C5x C 18.4357 -18.4465
8 C5x C 18.4475 -15.6443
9 C8y C 19.6519 -16.3466
10 C8y C 19.6393 -17.7439
11 C8y C 20.8442 -18.4571
12 C8x C 22.0618 -17.7657
13 C8x C 22.0743 -16.3684
14 C8y C 20.8693 -15.6622
15 O1a O 16.0068 -14.2381
16 O5x O 18.5059 -14.2381
17 N1b N 20.8580 -14.2592
18 O1a O 16.0068 -19.8426
19 O5x O 18.4219 -19.8426
20 N1b N 20.8369 -19.8566
21 C1b C 22.0691 -13.5480
22 C1b C 23.2800 -14.2521
23 N1b N 24.4910 -13.5409
24 C1b C 25.7021 -14.2450
25 C1b C 26.9130 -13.5339
26 O1a O 28.1241 -14.2381
27 C1b C 22.0480 -20.5536
28 C1b C 23.2589 -19.8495
29 N1b N 24.4699 -20.5465
30 C1b C 25.6810 -19.8426
31 C1b C 26.8919 -20.5396
32 O1a O 28.1030 -19.8355
33 X Cl 31.9160 -17.2232
34 X Cl 31.9160 -17.2232
BOND 34
1 4 15 1
2 6 7 1
3 8 16 2
4 7 10 1
5 14 17 1
6 9 8 1
7 3 18 1
8 8 5 1
9 7 19 2
10 5 4 2
11 11 20 1
12 4 1 1
13 17 21 1
14 21 22 1
15 1 2 2
16 22 23 1
17 2 3 1
18 23 24 1
19 3 6 2
20 24 25 1
21 9 10 2
22 25 26 1
23 10 11 1
24 20 27 1
25 11 12 2
26 27 28 1
27 12 13 1
28 28 29 1
29 13 14 2
30 29 30 1
31 14 9 1
32 30 31 1
33 5 6 1
34 31 32 1
BRACKET 1 30.5900 -18.1300 30.5900 -16.3100
1 32.8300 -16.3100 32.8300 -18.1300
1 2
ORIGINAL 1 33
REPEAT 1 34
|